Cited by 720Atrial Fibrillation Management and OutcomesCardiac Arrhythmias and TreatmentsCardiac pacing and defibrillation studies

Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation

Open access
Cosedis Nielsen, Jens, Johannessen, Arne, Raatikainen, Pekka, Hindricks, Gerhard, Walfridsson, Håkan, Kongstad, Ole, Pehrson, Steen, Englund, Anders +3 more·2012·New England Journal of Medicine

Abstract

BACKGROUND: There are limited data comparing radiofrequency catheter ablation with antiarrhythmic drug therapy as first-line treatment in patients with paroxysmal atrial fibrillation. METHODS: We randomly assigned 294 patients with paroxysmal atrial fibrillation and no history of antiarrhythmic drug use to an initial treatment strategy of either radiofrequency catheter ablation (146 patients) or therapy with class IC or class III antiarrhythmic agents (148 patients). Follow-up included 7-day Holter-monitor recording at 3, 6, 12, 18, and 24 months. Primary end points were the cumulative and per-visit burden of atrial fibrillation (i.e., percentage of time in atrial fibrillation on Holter-monitor recordings). Analyses were performed on an intention-to-treat basis. RESULTS: There was no significant difference between the ablation and drug-therapy groups in the cumulative burden of atrial fibrillation (90th percentile of arrhythmia burden, 13% and 19%, respectively; P=0.10) or the burden at 3, 6, 12, or 18 months. At 24 months, the burden of atrial fibrillation was significantly lower in the ablation group than in the drug-therapy group (90th percentile, 9% vs. 18%; P=0.007), and more patients in the ablation group were free from any atrial fibrillation (85% vs. 71%, P=0.004) and from symptomatic atrial fibrillation (93% vs. 84%, P=0.01). One death in the ablation group was due to a procedure-related stroke; there were three cases of cardiac tamponade in the ablation group. In the drug-therapy group, 54 patients (36%) underwent supplementary ablation. CONCLUSIONS: In comparing radiofrequency ablation with antiarrhythmic drug therapy as first-line treatment in patients with paroxysmal atrial fibrillation, we found no significant difference between the treatment groups in the cumulative burden of atrial fibrillation over a period of 2 years. (Funded by the Danish Heart Foundation and others; MANTRA-PAF ClinicalTrials.gov number, NCT00133211.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1113566

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Catheter ablation or combination therapy is often effective when antiarrhythmic drugs fail.

    “Catheter ablation or combination therapy is often effective when antiarrhythmic drugs fail.226,[585][586][587]”
  • The complication rate of atrial fibrillation ablation is similar to the complication rate for antiarrhythmic drugs.

    “AF ablation, when performed in experienced centres by adequately trained teams, is more effective than antiarrhythmic drug therapy in maintaining sinus rhythm, and the complication rate, though not negligible, is similar to the complication rate for antiarrhythmic drugs.585,717,1042”
  • Atrial fibrillation ablation, when performed in experienced centres by adequately trained teams, is more effective than antiarrhythmic drug therapy in maintaining sinus rhythm.

    “AF ablation, when performed in experienced centres by adequately trained teams, is more effective than antiarrhythmic drug therapy in maintaining sinus rhythm, and the complication rate, though not negligible, is similar to the complication rate for antiarrhythmic drugs.585,717,1042”
  • Complication rates were similar between catheter ablation and antiarrhythmic drug therapy as first-line treatment for paroxysmal atrial fibrillation.

    “Complication rates were similar, but ablation was performed in expert centres, justifying catheter ablation as first-line therapy in selected patients with paroxysmal AF who ask for interventional therapy.”
  • As first-line treatment for paroxysmal atrial fibrillation, randomized trials showed only modestly improved rhythm outcome with catheter ablation compared to antiarrhythmic drug therapy.

    “As first-line treatment for paroxysmal AF, randomized trials showed only modestly improved rhythm outcome with catheter ablation compared to antiarrhythmic drug therapy.585,[721][722][723]”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Kirchhof P, Auricchio A, Bax J, et al. Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J 2007;28:2803-17.

Cited by

Sorted by citations

Authors
Cosedis Nielsen, J., Johannessen, A., Raatikainen, P., Hindricks, G., Walfridsson, H., Kongstad, O., Pehrson, S., Englund, A., Hartikainen, J., Mortensen, L. S., & Hansen, P. S.
Affiliations
  • Gentofte Hospital (DK)
  • Tampere University Hospital (FI)
  • University Hospital Leipzig (DE)
  • Linköping University Hospital (SE)
  • Skåne University Hospital (SE)
  • Rigshospitalet (DK)
  • Örebro University Hospital (SE)
  • Kuopio University Hospital (FI)
  • Aarhus University Hospital (DK)
Venue
New England Journal of Medicine
Published
2012-10-25
Volume
367
Issue
17
Pages
1587-1595
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2164489173
Cited by
720
References
26
Citations by year
2026: 18 · 2025: 42 · 2024: 60 · 2023: 33 · 2022: 73 · 2021: 79 · 2020: 58 · 2019: 39 · 2018: 38 · 2017: 50 · 2016: 53 · 2015: 44 · 2014: 68 · 2013: 54 · 2012: 8
FWCI
35.82
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Lund University Publications (Lund University) (submittedVersion, other-oa)
Funders
  • Sanofi
  • Hjerteforeningen (05-4-B284-A466-22237)
  • Foundation for Cardiovascular Research
  • Sydäntutkimussäätiö
  • St. Jude Medical
  • Biosense Webster
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Arrhythmias and Treatments
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac pacing and defibrillation studies
Keywords
paroxysmal atrial fibrillation, radiofrequency catheter ablation, antiarrhythmic drugs, class Ic antiarrhythmic drugs, class III antiarrhythmic agents, first-line therapy, arrhythmia burden, symptomatic atrial fibrillation, cardiac tamponade
MeSH terms
Aged, Anti-Arrhythmia Agents, Atrial Fibrillation, Atrial Flutter, Female, Flecainide, Follow-Up Studies, Humans, Male, Middle Aged, Propafenone, Quality of Life, Electrocardiography, Ambulatory, Treatment Outcome, Catheter Ablation, Cost of Illness, Statistics, Nonparametric, Intention to Treat Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review